-
The prevalence of bacterial resistance to antibiotics has risen globally since mid-1990s, posing a severe risk to public health (1). Multidrug-resistant (MDR) organisms, which were defined as a strain resistant to three or more classes of antimicrobial drugs within the antimicrobial spectrum, pose an increasing challenge to global health.
Despite the increasing global attention to MDR infection, little research has been conducted on MDR infections in non-adult populations. Few available data suggested that epidemiology, risk factors, and outcomes of MDR infections were comparable with those observed in adults (2).
Most of the MDR organisms in Chinese children showed decreasing trends in recent years, except for imipenem-resistant Escherichia coli, imipenem-resistant Klebsiella pneumoniae, and methicillin-resistant Staphylococcus aureus (MRSA) (2). It is undeniable that multidrug-resistant bacterial infections lead to longer hospital stays and higher mortality rate (3). Among them, carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), carbapenem-resistant Enterobacteriaceae (CRE), and extended spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) were classified as critical priority pathogens and MRSA as high priority pathogen in the Priority Pathogens List of the World Health Organization (WHO). Infections caused by those key pathogens have aroused wide public concern.
Constant surveillance of the epidemiological trends of drug-resistant organisms is critical since MDR infections remain strongly associated with treatment failures and high mortality rates, particularly among pediatric patients. This report provides valuable information on MDR organism infections in non-adults in Zhejiang Province that could help facilitate better infection control and healthcare.
-
The overall prevalences of the five key pathogens were lower than that recorded in the China Antimicrobial Resistance Surveillance System (CARSS) and Infectious Diseases Surveillance of Pediatrics (ISPED). Comparison of results from ISPED 2017–2019 (4-6) indicated that the prevalence of CRE not only remained at a low level (2.0% to 2.7% from our data vs. 8.2% to 10.8% from ISPED), but also exhibited a decreasing trend since 2016 (P=0.004, <0.05). The only exception is carbapenem-resistant Klebsiella pneumonia, being an upward trend observable in ISPED (6). Though the prevalence of CRPA was lower than the data from ISPED (5), the prevalence has risen continuously since 2017. ESBL-E decreased since 2014 but the prevalence remained at a high level. The decrease was also observed in CRAB since 2015 and the prevalence recorded each year was lower than that of CARSS (2). The prevalence of MRSA kept increasing in the first few years (24.3% in 2014 to 29.2% in 2018) but then fell in 2019 (27.2%). The trend and prevalence of MRSA was in general agreement with the report of CARSS (27.5%–29.5%) (2). These data suggested that the prevalence of MRSA and CRPA should be prioritized due to their high prevalence and increasing trends.
Investigating the pattern of pathogens in the ICU environment, especially for MDR organisms, will help develop specific prevention and control strategies. A recent study in a tertiary teaching hospital in western China reported that Acinetobacter baumannii was the leading cause of infection in almost every ICU (7). In this study, ESBL-E was the most prevalent pathogen in ICU non-adult patients in Zhejiang Province (43.4% to 53.8%). High prevalences of CRAB, CRPA, and MRSA were also reported, suggesting a complex ICU environment. Risk analysis identified ICU admission as a risk factor for MDR infection, especially those due to CRAB (OR ranged from 4.4 to 12.0) and CRPA (OR ranged from 4.6 to 9.5). This finding is consistent with previous studies (8-9). Therefore, monitoring the pathogens exposure and incident infections in ICU environment is critical.
Bloodstream infections (BSIs) represent a major cause of mortality and morbidity worldwide. In addition, antimicrobial-resistant organisms, most notably MRSA and ESBL-E, have emerged as the important etiological agents of community-acquired BSI (10). In our study, the prevalence of ESBL-E was the most common pathogen of bloodstream infections, followed by MRSA. The results agreed with the observations from a population-based and large multicenter cohort study in the US and Europe (11). The high prevalence of ESBL-E may be related to inappropriate antibiotic use. One study showed that clinical isolation of ESBL-producing E. coli or ESBL-producing Klebsiella spp. was closely linked to the third-generation cephalosporin treatment (12).
In China, third-generation cephalosporin is the most common antibiotics to treat infections in neonates and older children and therefore may be overused in hospitals (13). MRSA is another critical pathogen associated with significant clinical morbidity and mortality. The prevalence of MRSA in adults is stable in Zhejiang Province and is similar to that in children (from 33.0% in 2014 to 29.8% in 2017) according to the China Antimicrobial Surveillance Network (14). In addition, the MDR pathogens responsible for BSI vary significantly in different regions in China. The predominant pathogen of BSI in our study is ESBL-E, whereas MRSA was the predominant BSI pathogen in Hubei Province (15). Risk analysis indicated that BSI had been a risk factor for CRE infection for many years, but a significant difference was not observed among other bacterial groups.
Surveillance carried out in Zhejiang Province indicated that great attention should be paid to MDR organisms, especially for CRPA and MRSA. Some measures should be taken to alleviate the threat of AMR. On the one hand, for hospital-acquired infections, it is necessary to monitor the ICU environment, where broad-spectrum antibiotic use and the presence of MDR bacteria are common. On the other hand, antimicrobial stewardship programs should be advocated, especially for antibiotic prescription in the community since, in accordance with China Health Care Policy, pediatric patients were referred to community hospitals first, where the misuse and overuse of antibiotics occur frequently. Encouragingly, the government of China has started explorations of AMR. In 2016, National Action Plan for Containing Antibacterial Resistance (2016–2020) was published, aiming at reducing antimicrobial resistance through the synergy between national, regional, and local levels. Surveillance of MDR pathogens in clinical patients is necessary for monitoring AMR.
There were some limitations in this surveillance study. First, due to the differences in medical conditions, data collected from hospitals in rural areas might be lower than the actual value. Second, symptomatic patients were more likely to visit medical institutions compared with asymptomatic ones, which may lead to selection bias. Finally, the lack of available data on antibiotic prescription in the community may influence the analysis of community-sourced infection.
In conclusion, conducting surveillance of multidrug-resistant bacterial infections in non-adult patients to depict the prevalence and variation trends will support better diagnosis and clinical treatment.
Pathogens ICU 2014 2015 2016 Positive Prevalence
(%) (95% CI)Odds ratio (95% CI) P Positive Prevalence
(%) (95% CI)Odds ratio (95% CI) P Positive Prevalence
(%) (95% CI)Odds ratio (95% CI) P CRAB (n=889) Yes 50 38.8 (30.3–47.7) 7.4 (4.7–11.5) <0.001 113 50.5 (43.3–56.7) 6.7 (4.9–9.3) <0.001 110 43.7 (37.4–50.0) 12.0 (8.2–17.5) <0.001 No 60 7.9 (6.1–10.0) 1 130 12.9 (10.9–15.2) 1 51 6.1 (4.5–7.9) 1 CRE (n=6,278) Yes 17 5.7 (3.3–8.9) 3.3 (2.0–5.6) <0.001 54 7.1 (5.4–9.2) 3.3 (2.4–4.4) <0.001 54 6.0 (4.5–7.7) 2.6 (1.9–3.5) <0.001 No 107 1.8 (1.5–2.2) 1 210 2.3 (2.0–2.6) 1 239 2.4 (2.1–2.7) 1 CRPA (n=604) Yes 18 31.0 (19.5–44.5) 9.4 (4.7–18.6) <0.001 31 24.4 (24.7–45.2) 9.5 (5.6–16.1) <0.001 30 29.1 (20.6–38.9) 7.2 (4.3–12.1) <0.001 No 25 4.6 (3.0–6.7) 1 43 5.3 (3.8–7.0) 1 48 5.4 (4.0–7.1) 1 MRSA (n=4,361) Yes 33 21.4 (15.2–28.2) 0.8 (0.6–1.2) 0.393 101 40.9 (34.7–47.3) 2.0 (1.5–2.5) <0.001 108 41.2 (35.2–47.4) 2.0 (1.5–2.6) <0.001 No 1,028 24.4 (23.1–25.8) 1 1,824 26.1 (25.1–27.2) 1 1,852 26.1 (25.1–27.1) 1 ESBL–E (n=4,124) Yes 93 45.1 (38.2–52.2) 1.1 (0.8–1.5) 0.467 254 49.3 (44.9–53.7) 1.4 (1.1–1.6) 0.001 307 47.2 (43.3–51.1) 1.4 (1.2–1.7) <0.001 No 1,668 42.6 (41.0–44.1) 1 2,525 41.9 (40.6–43.1) 1 2565 38.6 (37.4–39.8) 1 Pathogens ICU 2017 2018 2019 Positive Prevalence
(%) (95% CI)Odds ratio (95% CI) P Positive Prevalence
(%) (95% CI)Odds ratio (95% CI) P Positive Prevalence
(%) (95% CI)Odds ratio (95% CI) P CRAB (n=889) Yes 86 32.2 (26.6–38.2) 6.1 (4.2–8.9) <0.001 84 40.0 (34.2–48.0) 7.7 (5.3–11.2) <0.001 33 24.4 (17.5–32.6) 4.4 (2.7–7.3) <0.001 No 55 7.2 (5.5–9.3) 1 64 8.3 (6.4–10.5) 1 45 6.8 (5.0–9.0) 1 CRE (n=6,278) Yes 56 5.3 (4.0–6.8) 2.8 (2.1–3.8) <0.001 41 4.9 (3.5–6.5) 2.7 (1.9–3.8) <0.001 38 4.7 (3.3–6.4) 2.5 (1.8–3.6) <0.001 No 189 1.9 (1.7–2.2) 1 174 1.8 (1.6–2.1) 1 170 1.9 (1.6–2.2) 1 CRPA (n=604) Yes 26 23.9 (16.2–33.0) 5.8 (3.4–9.8) <0.001 39 33.1 (24.7–42.3) 5.6 (3.6–8.7) <0.001 36 33.3 (24.6–43.1) 4.6 (2.9–7.3) <0.001 No 46 5.1 (3.8–6.8) 1 88 8.1 (6.5–9.9) 1 77 9.8 (7.8–12.1) 1 MRSA (n=4,361) Yes 83 29.0 (23.8–34.7) 1.0 (0.8–1.3) 0.883 123 41.4 (35.5–46.9) 1.7 (1.4–2.2) <0.001 102 34.3 (29.0–40.0) 1.4 (1.1–1.8) 0.005 No 2,058 28.6 (27.6–29.7) 1 2,238 28.8 (27.7–29.8) 1 2,118 27.0 (26.0–28.0) 1 ESBL–E (n=4,124) Yes 411 52.8 (49.2–56.3) 1.7 (1.4–1.9) <0.001 320 53.8 (49.7–57.8) 1.9 (1.6–2.2) <0.001 258 43.4 (39.4–47.5) 1.2 (1.0–1.4) 0.034 No 2,630 40.0 (38.8–41.2) 1 2,464 38.0 (36.8–39.2) 1 2,263 39.0 (37.7–40.2) 1 Abbreviations: CRAB=carbapenem-resistant Acinetobacter baumannii; CRE=carbapenem-resistant Enterobacteriaceae; CRPA=carbapenem-resistant Pseudomonas aeruginosa; MRSA=methicillin-resistant Staphylococcus aureus; ESBL-E=extended-spectrum β-lactamase-producing Enterobacteriaceae. Table 1. Prevalence and risk analysis of critical pathogens in intensive care unit (ICU) and non-ICU groups in non-adult patients — Zhejiang Province, 2014–2019.
Pathogens Age group, years 2014 2015 2016 Positive Prevalence
(%) (95% CI)Odds ratio (95% CI) P Positive Prevalence
(%) (95% CI)Odds ratio (95% CI) P Positive Prevalence
(%) (95% CI)Odds ratio (95% CI) P CRAB (n=889) <1 23 14.9 (9.7–21.6) 1.9 (1.1–3.3) <0.001 113 28.8 (24.4–33.6) 3.0 (2.2–4.3) <0.001 71 23.1 (18.5–28.3) 5.7 (3.5–9.2) <0.001 1–5 39 8.6 (6.2–11.5) 1 61 11.8 (9.1–14.8) 1 25 5.0 (3.3–7.3) 1 6–14 26 12.0 (8.0–17.1) 1.5 (0.9–2.5) 37 14.5 (10.4–19.4) 1.3 (0.8–2.0) 41 17.6 (12.9–23.1) 4.0 (2.4–6.8) 15–17 22 34.9 (23.3–48.0) 5.7 (3.1–10.6) 32 50.8 (37.9–63.6) 7.8 (4.4–13.6) 24 44.4 (30.9–58.6) 15.2 (7.8–29.7) CRE (n=6,278) <1 16 1.0 (0.6–1.7) 1 0.014 82 2.8 (2.2–3.4) 1 <0.001 94 3.0 (2.4–3.6) 1 <0.001 1–5 66 2.3 (1.8–3.0) 1.3 (1.3–4.0) 96 2.4 (1.9–2.9) 0.9 (0.6–1.2) 92 2.2 (1.8–2.7) 0.7 (0.5–1.0) 6–14 31 2.1 (1.4–2.9) 2.0 (1.1–3.7) 54 2.2 (1.6–2.8) 0.8 (0.5–1.1) 71 2.5 (2.2–3.2) 0.9 (0.6–1.2) 15–17 11 2.8 (1.4–5.0) 2.8 (1.3–6.0) 32 6.3 (4.4–8.8) 2.4 (1.6–3.6) 36 6.3 (4.4–8.5) 2.2 (1.5–3.2) CRPA (n=604) <1 8 8.5 (3.7–16.1) 2.9 (1.0–7.9) 0.014 20 11.0 (6.9–16.5) 2.1 (1.1–4.1) 0.009 27 15.7 (10.6–22.0) 3.4 (1.9–6.2) <0.001 1–5 8 3.1 (1.4–6.1) 1 20 5.5 (3.4–8.3) 1 21 5.2 (3.3–7.9) 1 6–14 13 6.4 (3.5–10.7) 2.1 (0.9–5.2) 23 7.8 (5.0–11.5) 1.5 (0.8–2.7) 24 7.2 (4.7–10.5) 1.4 (0.8–2.6) 15–17 14 26.9 (15.6–41.0) 11.4 (4.5–28.9) 11 16.4 (8.5–27.5) 3.4 (1.5–7.5) 6 7.1 (2.7–14.9) 1.4 (0.5–3.6) MRSA (n=4,361) <1 330 36.8 (33.6–40.0) 3.5 (2.3–5.2) <0.001 497 30.9 (28.6–33.2) 1.3 (1.0–1.6) <0.001 531 27.8 (25.8–29.9) 1.1 (0.8–1.4) 0.308 1–5 465 22.6 (20.8–24.5) 1.7 (1.2–2.6) 924 26.0 (24.6–27.5) 1.0 (0.8–1.3) 890 26.8 (25.3–28.4) 1.1 (0.8–1.3) 6–14 236 19.7 (17.5–22.1) 1.5 (1.0–2.2) 418 24.0 (22.0–26.1) 0.9 (0.7–1.2) 456 25.1 (23.2–27.2) 0.9 (0.7–1.2) 15–17 30 14.4 (9.9–19.9) 1 86 26.2 (21.5–31.3) 1 83 26.2 (21.4–31.4) 1 ESBL–E (n=4,124) <1 556 53.0 (49.9–56.1) 2.0 (1.5–2.7) <0.001 1,002 52.1 (49.8–54.4) 2.0 (1.6–2.6) <0.001 1025 44.8 (42.8–46.9) 1.6 (1.2–2.0) <0.001 1–5 738 40.2 (38.0–42.5) 1.2 (0.9–1.6) 1,004 39.4 (37.5–41.3) 1.2 (0.9–1.5) 970 36.7 (34.9–38.6) 1.1 (0.9–1.4) 6–14 383 38.0 (35.0–41.1) 1.1 (0.8–1.5) 665 37.6 (35.4–39.9) 1.1 (0.9–1.4) 762 37.4 (35.3–39.6) 1.2 (0.9–1.5) 15–17 84 35.9 (29.8–42.4) 1 108 35.2 (29.8–40.8) 1 115 33.9 (28.9–39.2) 1 Pathogens Age group, years 2017 2018 2019 Positive Prevalence
(%) (95% CI)Odds ratio (95% CI) P Positive Prevalence
(%) (95% CI)Odds ratio (95% CI) P Positive Prevalence
(%) (95% CI)Odds ratio (95% CI) P CRAB (n=889) <1 41 14.6 (10.7–19.3) 1.8 (1.1–2.9) <0.001 27 11.9 (8.0–16.8) 1.4 (0.8–3.2) <0.001 16 8.2 (4.8–13.0) 0.9 (0.5–1.7) <0.001 1–5 35 8.8 (6.2–12.0) 1 39 8.9 (6.4–11.9) 1 31 9.0 (6.2–12.5) 1 6–14 38 14.1 (10.2–18.9) 1.7 (1.0–2.8) 42 18.4 (13.6–24.1) 2.3 (1.4–3.7) 19 8.8 (5.4–13.3) 1.0 (0.5–1.8) 15–17 27 33.8 (23.6–45.2) 5.3 (3.0–9.4) 40 48.2 (37.1–59.4) 9.5 (5.6–16.4) 12 28.6 (15.7–44.6) 4.0 (1.9–8.7) CRE (n=6,278) <1 83 2.7 (2.1–3.3) 1 0.002 74 2.2 (1.8–2.8) 1 <0.001 75 2.4 (1.9–3.0) 1 0.014 1–5 70 1.8 (1.4–2.2) 0.7 (0.5–0.9) 55 1.5 (1.2–2.0) 0.7 (0.5–1.0) 59 1.8 (1.4–2.3) 0.7 (0.5–1.1) 6–14 68 2.1 (1.7–2.7) 0.8 (0.6–1.1) 59 2.1 (1.6–2.7) 0.9 (0.7–1.3) 53 1.9 (1.4–2.5) 0.8 (0.5–1.1) 15–17 24 4.0 (2.6–5.9) 1.5 (1.0–2.4) 27 4.6 (3.0–6.6) 2.1 (1.3–3.3) 21 3.8 (2.3–5.7) 1.6 (1.0–2.6) CRPA (n=604) <1 14 7.9 (4.4–12.8) 1.8 (0.8–3.6) 0.007 24 10.6 (6.9–15.2) 1.5 (0.8–2.5) <0.001 14 8.4 (4.7–13.7) 0.9 (0.5–1.7) 0.001 1–5 18 4.7 (2.8–7.3) 1 33 7.5 (5.2–10.4) 1 33 9.4 (6.6–13.0) 1 6–14 28 7.8 (5.2–11.0) 1.7 (0.9–3.2) 38 8.9 (6.4–12.1) 1.2 (0.7–2.0) 50 16.4 (12.5–21.1) 1.9 (1.2–3.0) 15–17 12 15.6 (8.3–25.6) 3.8 (1.7–8.2) 32 28.1 (20.1–37.3) 4.8 (2.8–8.3) 16 22.2 (13.3–33.6) 2.7 (1.4–5.3) MRSA (n=4,361) <1 638 32.1 (30.1–34.2) 1.3 (1.0–1.7) 0.001 709 31.5 (29.6–33.5) 1.1 (0.9–1.4) 0.041 597 29.5 (27.5–27.5) 1.1 (0.9–1.4) 0.074 1–5 890 27.4 (25.9–29.0) 1.1 (0.8–1.4) 939 28.4 (26.9–30.0) 1.0 (0.8–1.2) 933 26.4 (25.0–27.9) 1.0 (0.8–1.2) 6–14 534 27.5 (25.5–29.5) 1.1 (0.8–1.4) 599 28.0 (26.1–29.9) 0.9 (0.7–1.2) 586 26.4 (24.6–28.3) 1.0 (0.7–1.2) 15–17 79 26.3 (21.4–31.7) 1 114 29.5 (25.0–34.3) 1 104 27.3 (22.9–32.1) 1 ESBL–E (n=4,124) <1 1030 47.7 (25.5–49.8) 1.5 (1.2–1.9) <0.001 969 42.4 (40.4–44.5) 1.5 (1.2–1.9) <0.001 891 42.8 (40.7–45.0) 1.5 (1.2–1.9) <0.001 1–5 968 39.1 (37.2–41.1) 1.1 (0.9–1.3) 935 39.8 (37.8–41.8) 1.4 (1.1–1.7) 718 38.0 (35.8–40.2) 1.2 (1.0–1.6) 6–14 899 38.6 (36.6–40.6) 1.1 (0.8–1.3) 759 36.5 (34.4–38.6) 1.2 (0.9–1.5) 789 38.4 (36.2–40.5) 1.3 (1.0–1.6) 15–17 144 37.3 (32.5–42.3) 1 121 32.6 (27.9–37.6) 1 123 33.2 (28.4–38.2) 1 Abbreviations: CRAB=carbapenem-resistant Acinetobacter baumannii; CRE=carbapenem-resistant Enterobacteriaceae; CRPA=carbapenem-resistant Pseudomonas aeruginosa; MRSA=methicillin-resistant Staphylococcus aureus; ESBL-E=extended-spectrum β-lactamase-producing Enterobacteriaceae. Table 2. Prevalence and risk analysis of critical pathogen in different age groups of non-adult patients — Zhejiang Province, 2014–2019.
BSI 2014 2015 2016 Positive Prevalence
(%) (95% CI)Odds ratio (95% CI) P Positive Prevalence
(%) (95% CI)Odds ratio (95% CI) P Positive Prevalence
(%) (95% CI)Odds ratio (95% CI) P CRAB (n=889) Yes 5 23.8 (8.2–47.2) 2.3 (0.8–6.3) 0.202 6 20.0 (7.7–38.6) 1.0 (0.4–2.5) 0.973 5 20.0 (6.8–40.7) 1.5 (0.5–4.0) 0.641 No 105 12.1 (10.0–14.5) 1 237 19.8 (17.5–22.1) 1 156 14.6 (12.5–16.9) 1 CRE (n=6,278) Yes 6 2.3 (0.8–4.8) 1.2 (0.5–2.6) 0.737 23 4.8 (3.1–7.1) 1.9 (1.2–3.0) 0.003 23 4.3 (2.8–6.5) 1.7 (1.1–2.6) 0.018 No 118 2.0 (1.6–2.3) 1 241 2.5 (2.2–2.9) 1 270 2.6 (2.3–3.0) 1 CRPA (n=604) Yes 2 12.5 (1.6–38.3) 1.9 (0.4–8.7) 0.722 7 14.9 (6.2–28.3) 2.1 (0.9–4.8) 0.145 3 13.0 (2.8–33.6) 1.8 (0.5–6.2) 0.587 No 41 7.0 (5.0–9.3) 1 67 7.8 (6.1–9.8) 1 75 7.7 (6.1–9.6) 1 MRSA (n=4,361) Yes 25 29.1 (19.8–39.9) 1.3 (0.8–2.1) 0.301 49 34.3 (26.5–42.7) 1.4 (1.0–2.1) 0.037 56 31.5 (24.7–38.8) 1.3 (0.9–1.8) 0.141 No 1,036 24.2 (23.0–25.5) 1 1876 26.5 (25.5–27.5) 1 1904 26.5 (25.5–27.6) 1 ESBL–E (n=4,124) Yes 91 53.8 (46.0–61.5) 1.6 (1.2–2.2) 0.003 102 37.9 (32.1–44.0) 0.8 (0.6–1.1) 0.125 143 41.6 (36.3–47.0) 1.1 (0.9–1.4) 0.386 No 1,670 42.2 (40.7–43.8) 1 2,677 42.6 (41.4–43.9) 1 2,729 39.2 (38.1–40.4) 1 BSI 2017 2018 2019 Positive Prevalence
(%) (95% CI)Odds ratio (95% CI) P Positive Prevalence
(%) (95% CI)Odds ratio (95% CI) P Positive Prevalence
(%) (95% CI)Odds ratio (95% CI) P CRAB (n=889) Yes 7 26.9 (11.6–47.8) 2.4 (1.0–5.8) 0.091 9 33.3 (16.5–54.0) 2.9 (1.3–6.6) 0.016 3 16.7 (3.6–41.4) 1.9 (0.5–6.6) 0.554 No 134 13.4 (11.3–15.7) 1 139 14.6 (12.4–17.0) 1 75 9.6 (7.6–11.9) 1 CRE (n=6,278) Yes 29 5.9 (4.0–8.4) 2.9 (2.0–4.4) <0.001 14 3.0 (1.6–4.9) 1.5 (0.8–2.5) 0.174 18 4.3 (2.6–6.8) 2.2 (1.3–3.6) 0.002 No 216 2.1 (1.8–2.4) 1 201 2.1 (1.8–2.4) 1 190 2.0 (1.8–2.4) 1 CRPA (n=604) Yes 3 13.6 (2.9–34.9) 2.1 (0.6–7.2) 0.442 3 9.4 (2.0–25.0) 0.9 (0.3–2.9) 1 1 3.0 (0.1–15.8) 0.2 (0.0–1.5) 0.153 No 69 7.0 (5.5–8.8) 1 124 10.6 (8.9–12.5) 1 112 13.0 (10.9–15.5) 1 MRSA (n=4,361) Yes 33 25.8 (18.5–34.3) 0.9 (0.6–1.3) 0.471 52 34.9 (27.3–43.1) 1.3 (0.9–1.8) 0.123 41 29.3 (21.9–37.6) 1.1 (0.8–1.6) 0.581 No 2,108 28.7 (27.7–29.7) 1 2,309 29.1 (28.1–30.1) 1 2179 27.2 (26.2–28.2) 1 ESBL–E (n=4,124) Yes 145 43.4 (38.0–48.9) 1.1 (0.9–1.4) 0.44 134 41.6 (36.2–47.2) 1.1 (0.9–1.4) 0.385 117 41.2 (35.4–47.2) 1.1 (0.8–1.4) 0.522 No 2,896 41.3 (40.1–42.4) 1 2,650 39.2 (38.0–40.4) 1 2,404 39.3 (38.1–40.5) 1 Abbreviations: BSI=blood stream infection; CRAB=carbapenem-resistant Acinetobacter baumannii; CRE=carbapenem-resistant Enterobacteriaceae; CRPA=carbapenem-resistant Pseudomonas aeruginosa; MRSA=methicillin-resistant Staphylococcus aureus; ESBL-E=extended-spectrum β-lactamase-producing Enterobacteriaceae. Table 3. Prevalence and risk analysis of critical pathogen in BSI non-adult patients — Zhejiang Province, 2014–2019.
HTML
Citation: |